A predictor of response in HER2+ breast cancer—at last!
Author:
Affiliation:
1. Department of Pathology and Laboratory Medicine, Emory University , Atlanta, GA, USA
Funder
Department of Pathology
Emory University
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djac228/48769486/djac228.pdf
Reference21 articles.
1. Targeting HER2-positive breast cancer: advances and future directions;Swain;Nat Rev Drug Discov,2022
2. Comparison of HercepTest mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status;Ruschoff;Virchows Arch,2022
3. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria;Schalper;Arch Pathol Lab Med,2014
4. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform;Wu;Breast Cancer Res Treat,2018
5. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer;Wesseling;Virchows Arch,2016
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3